Therefore, the development of inhibitors against CDK4/6, the development of drug candidates targeting lncRNAs and the screening of natural compounds for adjuvant therapy are being anticipated as new strategies for the treatment of breast cancer using the cell cycle as a supportive point. This evidence concerns the gene CDK4 and breast cancer.